Hemoglobin interference limitation revised downward; hemolyzed samples may result in false negative results.
Source facts
Action
An Urgent Product Correction letter was mailed to each account, during the week of 4/21/03, advising them not to use hemolyzed specimens with a hemoglobin level equal to, or greater than, 0.1 g/dL.
Initiated
2003-04-25
Root cause
Other
Terminated
2003-06-19
Distribution
United States
Recall number
Z-0871-03
Recall status
Terminated
CDRH record ID
27064
FDA classified
2003-05-29
Recall event number
26091
Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.
Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.